30 results
6-K
EX-99.1
PPBT
Purple Biotech Ltd
2 May 24
Report of Foreign Private Issuer
4:13pm
Robust preclinical package No DLTs in monotherapy or in combination Early activity demonstrated RP2D determined at 100 mg/kg, Phase 1 concluded Clinical
6-K
EX-99.1
PPBT
Purple Biotech Ltd
6 Mar 24
Report of Foreign Private Issuer
4:06pm
li n i c al package No DLTs in monotherapy or in combination Early activity demonstrated RP2D determined at 100 mg/kg, Phase 1 concluded C li n i c
6-K
EX-99.1
PPBT
Purple Biotech Ltd
21 Nov 23
Report of Foreign Private Issuer
4:00pm
and in combination Uniquely positioned to tackle resistance to EGFRi, MAPKi and ICI Robust p r ecl i ni c al package No DLTs in monotherapy or in combination Early
6-K
EX-99.1
PPBT
Purple Biotech Ltd
13 Oct 23
Report of Foreign Private Issuer
7:09am
Robust preclinical package No DLTs in monotherapy or in combination Early activity demonstrated Clinical Stage Opportunity to establish a Standard
6-K
EX-99.1
3w9je31k
13 Sep 23
Report of Foreign Private Issuer
8:39am
6-K
EX-99.1
9r3obm27pz3 g8
1 May 23
Notice of Annual General Meeting of Shareholders
4:00pm
6-K
EX-99.1
ov4pohppmk1jd w179n5
9 Nov 22
Report of Foreign Private Issuer
4:11pm
6-K
EX-99.1
w72nwaw y79vcd
6 Jun 22
Report of Foreign Private Issuer
7:33am
20-F/A
7xx9x3z
16 Mar 21
Annual report (foreign) (amended)
3:22pm
6-K
EX-99.1
17aefv9elydd
2 Jul 20
Extraordinary General Meeting of Shareholders
4:19pm
20-F/A
EX-4.27
6ilzr
31 Mar 20
Annual report (foreign) (amended)
4:45pm
424B3
wogion71
27 Dec 19
Prospectus supplement
4:30pm
6-K
EX-99.1
hpgwc gys
19 Nov 19
Report of Foreign Private Issuer
4:31pm
20-F/A
EX-4.15
8x0wm sllgcg3dz8gy
3 Apr 19
Annual report (foreign) (amended)
7:38am